PL378333A1 - Sposoby profilaktyki i leczenia choroby Alzheimera (AD) - Google Patents

Sposoby profilaktyki i leczenia choroby Alzheimera (AD)

Info

Publication number
PL378333A1
PL378333A1 PL378333A PL37833304A PL378333A1 PL 378333 A1 PL378333 A1 PL 378333A1 PL 378333 A PL378333 A PL 378333A PL 37833304 A PL37833304 A PL 37833304A PL 378333 A1 PL378333 A1 PL 378333A1
Authority
PL
Poland
Prior art keywords
arg
glu
asp
tyr
phe
Prior art date
Application number
PL378333A
Other languages
English (en)
Other versions
PL209989B1 (pl
Inventor
Frank Mattner
Original Assignee
Affiris Forschungs-Und Entwicklungs Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Forschungs-Und Entwicklungs Gmbh filed Critical Affiris Forschungs-Und Entwicklungs Gmbh
Publication of PL378333A1 publication Critical patent/PL378333A1/pl
Publication of PL209989B1 publication Critical patent/PL209989B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
PL378333A 2003-01-14 2004-01-13 Zastosowanie związku peptydowego oraz szczepionka przeciwko chorobie Alzheimera PL209989B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT362003 2003-01-14
AT0146403A AT413945B (de) 2003-01-14 2003-09-17 Impfstoff für die alzheimer-krankheit
PCT/EP2004/000162 WO2004062556A2 (en) 2003-01-14 2004-01-13 Methods for preventing and treating alzheimer’s disease (ad)

Publications (2)

Publication Number Publication Date
PL378333A1 true PL378333A1 (pl) 2006-03-20
PL209989B1 PL209989B1 (pl) 2011-11-30

Family

ID=32714004

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378333A PL209989B1 (pl) 2003-01-14 2004-01-13 Zastosowanie związku peptydowego oraz szczepionka przeciwko chorobie Alzheimera

Country Status (15)

Country Link
US (2) US7732568B2 (pl)
EP (2) EP1679319B1 (pl)
JP (2) JP4547373B2 (pl)
CN (2) CN102526699A (pl)
AT (3) AT413945B (pl)
CA (1) CA2513218C (pl)
CY (2) CY1107146T1 (pl)
DE (2) DE602004009705T2 (pl)
DK (2) DK1679319T3 (pl)
ES (2) ES2296084T3 (pl)
HK (1) HK1091499A1 (pl)
PL (1) PL209989B1 (pl)
PT (2) PT1583774E (pl)
SI (1) SI1583774T1 (pl)
WO (1) WO2004062556A2 (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056318A2 (en) 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
EP1711208A2 (en) * 2004-01-28 2006-10-18 Curix APS Conjugates of amyloid proteins as vaccines for amyloid-related diseases
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
JP5475994B2 (ja) 2005-11-30 2014-04-16 アッヴィ・インコーポレイテッド 抗Ａβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。
KR101434935B1 (ko) 2005-11-30 2014-10-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의용도
RS53291B (en) 2005-12-12 2014-08-29 Ac Immune S.A. BETA 1-42 SPECIFIC MONOCLONIC ANTIBODIES WITH THERAPEUTIC PROPERTIES
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
KR101605207B1 (ko) 2006-07-14 2016-03-22 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
CN104761641A (zh) * 2007-06-12 2015-07-08 Ac免疫有限公司 β淀粉样蛋白的人源化抗体
CN101883790B (zh) * 2007-10-05 2015-09-09 基因技术公司 抗淀粉样蛋白β抗体在眼病中的用途
SG185277A1 (en) * 2007-10-05 2012-11-29 Genentech Inc Humanized antibody
EP2205632B1 (en) * 2007-10-05 2016-11-16 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
US8586706B2 (en) 2007-10-25 2013-11-19 Kagoshima University Peptide vaccine using mimic molecules of amyloid β peptide
EP2224000B1 (en) * 2007-10-29 2020-05-13 TAO Health Life Pharma Co., Ltd. Antibody and use thereof
EP2278998A1 (en) 2008-04-17 2011-02-02 Declion Pharmaceuticals, Inc. Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
AT509611B1 (de) * 2008-06-12 2012-04-15 Affiris Forschungs-Und Entwicklungs Gmbh Vakzin
AU2009257170B2 (en) * 2008-06-12 2014-06-12 Affiris Ag Compounds for treating symptoms associated with Parkinson's disease
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
AU2011282536B2 (en) 2010-07-30 2015-12-24 Ac Immune S.A. Safe and functional humanized anti beta-amyloid antibody
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
GB201113570D0 (en) * 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
DK2579042T3 (da) 2011-10-04 2014-07-21 Affiris Ag Fremgangsmåde til at påvise Aß-specifikke antistoffer i en biologisk prøve
EP2787347A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
US10381614B2 (en) * 2013-04-17 2019-08-13 Samsung Sdi Co., Ltd. Battery module
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2017076873A1 (en) 2015-11-03 2017-05-11 Affiris Ag Method for vaccination against a self-antigen in a human patient
CN105237628B (zh) * 2015-11-17 2018-08-07 南开大学 一种用于治疗阿尔兹海默症的多肽
CN107022019B (zh) * 2016-11-24 2020-10-30 桂林医学院 一种用于脑内降铁除自由基的多肽、制备方法与应用
WO2023161528A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
GB9022190D0 (en) * 1990-10-12 1990-11-28 Perham Richard N Immunogenic material
US5639603A (en) * 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6088993A (en) 1999-02-05 2000-07-18 Irace; Francisco D. Closure system
CA2363118A1 (en) 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
US6703491B1 (en) * 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
DE60044057D1 (de) * 1999-09-03 2010-05-06 Univ Ramot Verbindungen, zusammensetzungen und verfahren zur behandlung oder vorsorge von alzheimer erkrankung
EP1267908B1 (en) * 2000-03-03 2004-05-06 GlaxoSmithKline Biologicals S.A. Vaccine for the treatment of atherosclerosis
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
ES2276732T3 (es) 2001-09-03 2007-07-01 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Mimotopos de antigenos y vacuna contra enfermedades cancerosas.
ATE434186T1 (de) * 2002-05-07 2009-07-15 Pasteur Institut Screeningverfahren für pp1-wechselwirkende polypeptide oder proteine, peptide, die die bindung von pp1c an die proteine bcl-2, bcl-xl und bcl-w hemmen, und ihre verwendung

Also Published As

Publication number Publication date
PL209989B1 (pl) 2011-11-30
CA2513218C (en) 2013-06-25
WO2004062556A2 (en) 2004-07-29
US20060111301A1 (en) 2006-05-25
EP1679319A1 (en) 2006-07-12
ATE376559T1 (de) 2007-11-15
ATA14642003A (de) 2005-11-15
AT413945B (de) 2006-07-15
US7732568B2 (en) 2010-06-08
DK1583774T3 (da) 2010-05-03
DE602004009705D1 (de) 2007-12-06
CY1107146T1 (el) 2012-05-23
ES2339447T3 (es) 2010-05-20
HK1091499A1 (en) 2007-01-19
WO2004062556A8 (en) 2004-10-21
DE602004025668D1 (de) 2010-04-08
JP2006515876A (ja) 2006-06-08
ES2339447T8 (es) 2011-05-26
ES2296084T3 (es) 2008-04-16
CY1110634T1 (el) 2015-04-29
PT1679319E (pt) 2008-01-10
JP5282058B2 (ja) 2013-09-04
JP2010174024A (ja) 2010-08-12
CN1826354B (zh) 2014-01-08
EP1583774B1 (en) 2010-02-24
EP1583774A2 (en) 2005-10-12
CN102526699A (zh) 2012-07-04
CA2513218A1 (en) 2004-07-29
ATE458753T1 (de) 2010-03-15
EP1679319B1 (en) 2007-10-24
WO2004062556A3 (en) 2004-09-16
DK1679319T3 (da) 2008-01-28
PT1583774E (pt) 2010-04-07
US20110015131A1 (en) 2011-01-20
CN1826354A (zh) 2006-08-30
AU2004204349A1 (en) 2004-07-29
DE602004009705T2 (de) 2008-06-05
SI1583774T1 (sl) 2010-06-30
JP4547373B2 (ja) 2010-09-22

Similar Documents

Publication Publication Date Title
SI1583774T1 (sl) Postopki za preprečevanje in zdravljenje Alzheimerjeve bolezni AD
TW200602071A (en) Methods for preventing and treating alzheimer's disease (ad)
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
AT500379B8 (de) Tau-proteine
WO2001039796A3 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
BR0213565A (pt) Anticorpo de anti-tnf alfa modificado
WO2004006952A3 (en) Therapeutic tuberculosis vaccines
WO2000073430A3 (de) Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind
DE60313437D1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4
WO2003068815A3 (en) Mhc class ii peptide epitope of 5t4 antigen
EE200000478A (et) Peptiid, seda kodeeriv geen, diagnostiline reagent ja diagnostiline reaktiivikomplekt ning vaktsiinkasutamiseks riketsioosi ravis
WO2004113386A3 (en) Modified hirudin proteins and t-cell epitopes in hirudin
HUP0303150A2 (hu) Csökkentett immunogenitású, módosított keratinocita növekedési faktor (KGF)
WO2002070563A3 (en) Nuclear hormone receptor ligand binding domain
WO2007030771A3 (en) Targeted identification of immunogenic peptides
HUP0402160A2 (hu) T-sejt-epitópok a karboxipeptidáz-G2-ben
WO2004050703A8 (en) Splice variant of the human pituitary growth hormone
AU2001281943A1 (en) The t-cell protein (tzon7), peptides and antibodies derived therefrom and uses thereof
WO2004011496A3 (en) Novel t-cell proteins, peptides and antibodies derived therefrom and uses thereof
WO2003070770A3 (en) Engineered human kunitz-type protease inhibitor
AU2002350406A1 (en) Identification of ses-3 (spr-5) in c. elegans and the uses of the same
WO2002070558A3 (en) Nuclear hormone receptor ligand binding domain
WO2002008393A3 (en) Serine protease from yersinia enterocolitica